Midazolam

Generic Name
Midazolam
Brand Names
Buccolam, Busulfex, Nayzilam, Seizalam
Drug Type
Small Molecule
Chemical Formula
C18H13ClFN3
CAS Number
59467-70-8
Unique Ingredient Identifier
R60L0SM5BC
Background

Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal...

Indication

Midazolam has different indications depending on its formulation by the FDA.

Nasal
...

Associated Conditions
Epileptic seizure, Status Epilepticus
Associated Therapies
Anaesthesia, Anxiolytic therapy therapy, Sedation for mechanically-ventilated patients, Preoperative amnesia therapy, Preoperative sedation therapy
Clinical Trials
Related News

Randomized Double-blind Trial of Midazolam and Loxapine in Agitated Patients

First Posted Date
2006-02-10
Last Posted Date
2015-03-11
Lead Sponsor
University Hospital, Rouen
Target Recruit Count
120
Registration Number
NCT00290082
Locations
🇫🇷

Emergency Department, St Etienne, France

🇫🇷

Emergecy department, Argenteuil, France

Family-Centered Behavioral Preparation for Surgery

Not Applicable
Completed
Conditions
Anxiety
First Posted Date
2005-12-02
Last Posted Date
2005-12-02
Lead Sponsor
Yale University
Target Recruit Count
400
Registration Number
NCT00261261
Locations
🇺🇸

Yale University, New Haven, Connecticut, United States

To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients

Phase 1
Completed
Conditions
Neoplasms, Breast
Interventions
Drug: Midazolam
Drug: Lapatinib
First Posted Date
2005-11-24
Last Posted Date
2017-12-06
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
24
Registration Number
NCT00258050
Locations
🇺🇸

GSK Investigational Site, Chapel Hill, North Carolina, United States

Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects

Phase 4
Completed
Conditions
Sedation
First Posted Date
2005-09-12
Last Posted Date
2008-10-16
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
224
Registration Number
NCT00158873
Locations
🇳🇱

GSK Investigational Site, Zwolle, Netherlands

Lorazepam Sedation for Critically Ill Children

First Posted Date
2005-04-28
Last Posted Date
2023-03-20
Lead Sponsor
The Emmes Company, LLC
Target Recruit Count
179
Registration Number
NCT00109395
Locations
🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers

Phase 4
Completed
Conditions
Healthy
HIV Infections
First Posted Date
2002-11-26
Last Posted Date
2017-07-02
Lead Sponsor
National Institutes of Health Clinical Center (CC)
Target Recruit Count
81
Registration Number
NCT00050180
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Pilot Study of Spinal Manipulation for Chronic Neck Pain

Phase 1
Terminated
Conditions
Neck Pain
First Posted Date
2002-01-30
Last Posted Date
2006-08-18
Lead Sponsor
National Center for Complementary and Integrative Health (NCCIH)
Target Recruit Count
30
Registration Number
NCT00030004
Locations
🇺🇸

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Randomized Study of Propofol Versus Fentanyl and Midazolam in Pediatric Patients Requiring Mechanical Ventilation and Sedation Therapy

Not Applicable
Completed
Conditions
Respiration Disorders
First Posted Date
1999-10-19
Last Posted Date
2015-03-25
Lead Sponsor
FDA Office of Orphan Products Development
Target Recruit Count
120
Registration Number
NCT00004424
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy